Identification of a common ketohexokinase-dependent link driving alcohol intake and alcohol-associated liver disease in mice.
Level 5 - mechanism / opinion, no new human data
Animal experiment evaluating genetic knockout and pharmacological inhibition in mice
PubMed 41214144 · doi:10.1038/s42255-025-01402-x
What was done
Researchers investigated whether endogenous fructose metabolism via ketohexokinase (KHK)-A/C mediates alcohol preference and alcohol-associated liver disease (ALD) in mice. They utilized global, conditional, hepatocyte-specific, and intestine-specific KHK-A/C knockout mice, as well as pharmacological KHK-A/C inhibition. Behavioral measures included two-bottle choice, conditioned place preference, operant self-administration, and ΔFosB expression in the nucleus accumbens. Liver pathology (steatosis, inflammation, and fibrosis) was evaluated under ethanol pair-matched feeding conditions, alongside assessments of portal vein osmolality, polyol pathway activation, and intestinal glucagon-like peptide-1 (GLP-1) levels.
What was found
Ethanol consumption elevated portal vein osmolality and activated the polyol pathway in the liver and intestine, generating fructose metabolized by KHK-A/C. Both genetic knockout and pharmacological inhibition of KHK-A/C reduced ethanol preference, conditioned place preference, operant self-administration, and nucleus accumbens ΔFosB expression. Hepatocyte-specific deletion partially reduced alcohol intake, while intestinal deletion restored GLP-1 levels. In ethanol pair-fed mice, global and liver-specific KHK-A/C knockouts showed substantial protection against hepatic steatosis, inflammation, and fibrosis. The abstract reports no numerical values or effect sizes.
Why it matters
This study links ethanol-induced endogenous fructose metabolism directly to both the neurological drive for alcohol consumption and the progression of alcohol-induced liver injury. Targeting KHK-A/C offers a potential dual therapeutic mechanism for alcohol use disorder and ALD.
Limits
The study was conducted entirely in rodent models, so findings may not translate to humans. The abstract omits sample sizes, quantitative effect estimates, and statistical confidence intervals. Potential adverse effects or compensatory metabolic shifts from chronic KHK-A/C inhibition were not described in the abstract.
Cited by
- supports In animal models, blocking fructose metabolism prevents the development of alcohol-induced fatty liver disease despite alcohol exposure.
- supports Alcohol consumption activates an enzyme that converts glucose to fructose, causing endogenous fructose synthesis in the liver.
- supports In animal models, blocking fructose metabolism or blocking aldose reductase prevents alcohol-induced fatty liver disease.